甲基乙二醛双（胍腙）用于非小细胞肺癌的II期试验

Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer.

作者信息

Chapman R, Kelsen D, Gralla R, Itri L, Casper E, Young C, Golbey R

出版信息

Cancer Clin Trials. 1981 Winter;4(4):389-91.

Abstract

Fifty-two patients with metastatic or recurrent non-small-cell lung cancer (NSCLC) were treated, during a phase II trial, with methylglyoxal-bis-(guanylhydrazone) (MGBG). Of the 44 patients who had adequate trials, 4 had partial responses (PR), for an overall 9% PR rate. Response durations ranged from 3 to 5+ months. Prior treatment with chemotherapy may have adversely affected response rate; 15% of previously untreated patients responded, compared to only 4% of previously treated patients. A syndrome of weakness and fatigue was the most serious side effect. Anorexia and weight loss, stomatitis, nausea and vomiting, diarrhea, and peripheral neuropathy were the other toxic effects. We conclude that MGBG has activity in NSCLC, especially in previously untreated patients, and further studies are indicated in that population.

摘要

在一项II期试验中，52例转移性或复发性非小细胞肺癌（NSCLC）患者接受了丙酮醛双（脒腙）（MGBG）治疗。在44例进行了充分试验的患者中，4例出现部分缓解（PR），总体PR率为9%。缓解持续时间为3至5个多月。先前接受化疗可能对缓解率产生不利影响；先前未接受治疗的患者中有15%出现缓解，而先前接受治疗的患者中只有4%出现缓解。虚弱和疲劳综合征是最严重的副作用。厌食和体重减轻、口腔炎、恶心和呕吐、腹泻以及周围神经病变是其他毒性作用。我们得出结论，MGBG在NSCLC中具有活性，尤其是在先前未接受治疗的患者中，并且该人群需要进一步研究。